# Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

> **NCT00807027** · PHASE3 · COMPLETED · sponsor: **GC Cell Corporation** · enrollment: 180 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Activated T lymphocyte(Immuncell-LC)

## Key facts

- **NCT ID:** NCT00807027
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807027, "Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00807027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*